. 2022 Jul 5;40(8):751–776. doi: 10.1007/s40273-022-01140-y

Table 2.

Hospital length of stay across included studies

Study	Country	Population	N	Outcome	Length of stay
LT-related hospitalisations
Aby et al. [21]	US	LT recipients with NASH cirrhosis or cryptogenic cirrhosis, 2002–2015		Post-transplant LOS, median days (IQR) Post-transplant hospital days in 1-yr, median (IQR)	Sarcopenia vs no sarcopenia: 44.5 (23.2–81.2) vs 46 (27–69.2); p = 0.812 53 (31.2–89.8) vs 55.5 (33.5–80); p = 0.777
Aby et al. [21]	US	With sarcopenia Without sarcopenia	90 56
Agopian et al. [22]	US	Patients who underwent primary LT, 1993–2011		All patients:
		Patients who underwent primary LT, 1993–2011		Total LOS, days	NASH vs non-NASH: 47 vs 36
		NASH aetiology Non-NASH aetiology HBV HCV ALD CC PBC/PSC	144 1150 691 127 185 58 89	Total LOS, days	HCV: 34; HBV: 27; ALD: 47; CC: 47; PBC/PSC: 35
				Post-transplant LOS, days	NASH vs non-NASH: 35 vs 29
				Post-transplant LOS, days	HCV: 28; HBV: 23; ALD: 36; CC: 36; PBC/PSC: 27
				Patients from home pre-transplant:
				Post-transplant LOS, days	NASH vs non-NASH: 28 vs 20
				Post-transplant LOS, days	HCV: 17; HBV: 17; ALD: 21; CC: 33; PBC/PSC: 22
				Hospitalised patients pre-transplant:
				Pre-transplant LOS, days	NASH vs non-NASH: 18 vs 18
				Pre-transplant LOS, days	HCV: 16; HBV: 16; ALD: 18; CC: 17; PBC/PSC: 18
				Post-transplant LOS, days	NASH vs non-NASH: 40 vs 42
				Post-transplant LOS, days	HCV: 38; HBV: 38; ALD: 46; CC: 37; PBC/PSC: 29
Barbas et al. [23]	Canada	NASH patients undergoing primary LT, 2000–2014			LDLT vs DDLT:
		NASH patients undergoing primary LT, 2000–2014		Post-transplant LOS, median days (IQR)	11 (8–16) vs 17 (10–31)
		LDLT DDLT	48 128	Post-transplant ICU LOS, mean days (SD)	3.2 (9.7) vs 6.3 (14.2)
		LDLT DDLT	48 128	Total LOS for index admission, median days (IQR)	12.5 (9–18) vs 19 (10–34)
Hoehn et al. [25]	US	Patients with diabetes who underwent LT, 2007–2011		Proportion of patients discharged home, %	NASH vs non-NASH^a: Obese: 71% vs 83%; p < 0.005 Non-obese: 79% vs 85%; p < 0.005
Hoehn et al. [25]	US	Total NASH	2971 713	LOS	NASH vs non-NASH^a: Non-obese: 10 vs 9 days; p < 0.05
Morris et al. [24]	US	Patients who underwent LSG following LT, 2014–2018	1	Post-transplant LSG LOS, median days (IQR)	2 (1–2)
Morris et al. [24]	US	Total NASH	15 14	Post-transplant LSG LOS, median days (IQR)	2 (1–2)
Cirrhosis-related hospitalisations
Axley et al. [27]	US	Hospital admissions for cirrhosis with ACLF (2006–2014)		LOS, mean days	Total: 2006–8: 13; 2009–11: 13; 2012–14: 12 NASH: 2006–14: 14
Axley et al. [27]	US	Total NASH-related	112,174 8903	LOS, mean days
NASH-related hospitalisations with or without comorbidities
Carruthers et al. [28]	England	Patients with biopsy-proven NASH (inpatient and day-case admissions to NHS hospitals 2004–2015)		LOS, median days (IQR)	2004–5 vs 2014–15: With diabetes: 2 (0–16) vs 0 (0–8); p < 0.001 Without diabetes: 1 (0–7) vs 0 (0–5); p < 0.001
Carruthers et al. [28]	England	With diabetes (2004–5) With diabetes (2014–15) Without diabetes (2004–5) Without diabetes (2014–15)	1303 2341 12,758 10,988	LOS, median days (IQR)
Geier et al. [29]	US, France, Germany	NASH patients (NASH-Atlas program July–November 2017)		LOS,^b mean (SD)	Total population: 3.7 (7.1) BC vs phenotypic NASH: 2.7 vs 6.0; p < 0.05 FR vs DE vs US: 5.0 vs 4.3 vs 2.1
		Total BC NASH Phenotypic NASH French NASH population German NASH population US NASH population	1216 786 430 227 287 702	LOS,^b mean (SD)
			1216 786 430 227 287 702	ICU LOS,^b mean (SD)	Total population: 0.4 (1.2) BC vs phenotypic NASH: 0.4 vs 0.4; p = ns FR vs DE vs US: 0.5 vs 0.3 vs 0.4
Reja et al. [31]	US	Hospitalised NASH patients with or without kidney failure, 2016		LOS, mean days (SD)	Total NASH: 4.8 (7.1) With vs without kidney failure: 6.4 (9.1) vs 3.1 (3.4), β/OR = 3.02 (95% CI 2.54–3.50; p < 0.0001)
Reja et al. [31]	US	Total With kidney failure Without kidney failure	1196 598 598	LOS, mean days (SD)

^aComparator inferred, but not explicitly stated in publication

^bNights in hospital/ICU

ACLF acute-on-chronic liver failure, ALD alcoholic liver disease, BC biopsy-confirmed, CC compensated cirrhosis, CI confidence interval, DDLT deceased donor liver transplant, DE German cohort, FR French cohort, HBV hepatitis B virus, HCV hepatitis C virus, ICU intensive care unit, IQR interquartile range, LDLT living donor liver transplantation, LOS length of stay, LSG laparoscopic sleeve gastrectomy, LT liver transplantation, NASH non-alcoholic steatohepatitis, NASH-Atlas Growth from Knowledge (currently Ipsos) Disease Atlas Real-World Evidence program, NHS National Health Service, ns non-significant, OR odds ratio, PBC primary biliary cirrhosis, PSC primary sclerosing cholangitis, SD standard deviation, US US cohort, yr year